A Phase 1/2 interventional study of Stem cells in Chronic Obstructive Lung Disease, sponsored by SMSbiotech. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by SMSbiotech · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.
Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 473rd largest by planned enrollment of the 1,037 interventional ones that give a count, is one of 39 that started in 2026, is one of 26 in phase 1/2, reaches primary completion later than 95 of the 171 other live ones, and was the 1,271st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 117 · Phase 2 230 · Phase 3 238 · Phase 4 98
First in 1994; this study’s year is marked. 39 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 100 across the 1,037 interventional studies, 171 across the 237 observational. Of the 1,018 that completed or were terminated, 502 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
603 of 1,278 have an industry lead sponsor. The 10 most frequent:
SMSbiotech is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
SMSbiotech has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
62 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT05879211Duke UniversityGoal Concordant Care Learning Laboratory | 2026-12 |
Add all 62 to your calendar (.ics) → With an account.
Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase 1b/2a, open-label, non-randomized, observation of 125 adults, with moderate to severe chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells).
The primary objective of this study is to evaluate the preliminary within-participant changes of SORT-COPD (SMS cells), in suspension, delivered to the lung as an aerosolized mist via a vibrating mesh nebulizer, on respiratory health status in participants with moderate to severe chronic obstructive pulmonary disease.
SORT-COPD II is a Phase 1b/2a, open-label, non-randomized, single-arm clinical study evaluating an investigational biologic therapy called SORT-COPD in adults with moderate to severe chronic obstructive pulmonary disease (COPD). SORT-COPD consists of Small Mobile Stem (SMS) cells suspended in Hank's Balanced Salt Solution and delivered directly to the lungs as an aerosolized mist using a vibrating mesh nebulizer.
SMS cells are small adult stem cells derived from human blood. Laboratory and animal studies suggest that these cells may bind to cells involved in lung repair and influence inflammatory, vascular, extracellular matrix, and tissue-repair processes. SORT-COPD is being investigated as a potential regenerative and disease-modifying therapy for COPD. However, its safety and potential clinical effects in people with COPD have not been fully established, and participation may not provide an individual medical benefit.
Up to 125 participants will be enrolled. The first 5 participants will form the Phase 1b portion of the study. These participants will receive the protocol-specified treatment regimen and will be followed through the Day 28 safety assessment. An independent Data Safety Monitoring Committee will then review the available safety and tolerability information before enrollment proceeds into Phase 2a.
If the Data Safety Monitoring Committee recommends continuation, an additional 120 participants will be enrolled in the Phase 2a portion. The Phase 2a portion is intended to further characterize safety and to estimate changes from baseline following treatment. The results will be used to inform the design of subsequent controlled clinical trials. The Data Safety Monitoring Committee will continue to review cumulative safety information during the study and may recommend that enrollment or treatment continue as planned, be temporarily paused, be modified, or be stopped.
All participants will receive the same treatment regimen. On each treatment day, participants will receive 2.4 billion SMS cells by oral inhalation through an Aerogen Solo vibrating mesh nebulizer used with an Aerogen Ultra device. Treatment will be administered at the study site on Days 1, 3, and 6, for a total planned dose of 7.2 billion SMS cells per participant.
For each treatment, three vials containing 0.8 billion SMS cells in 1 mL will be used. Each vial will be diluted with an additional 1 mL of Hank's Balanced Salt Solution before nebulization. The three diluted portions provide 6 mL of investigational cell suspension. After the cell suspension has been administered, an additional 3 mL of Hank's Balanced Salt Solution without SMS cells will be nebulized as a washout. The total nebulized volume on each treatment day will therefore be 9 mL. Administration is expected to take approximately 30 minutes.
Participants will undergo screening for up to 30 days before the first treatment. Study visits and assessments will include medical examinations, safety laboratory testing, electrocardiograms, monitoring for adverse events, pulmonary function testing, exercise assessments, respiratory questionnaires, and lung imaging. Participants will be monitored at the study site during and after each treatment. Follow-up will continue through approximately 12 months after treatment, and each participant is expected to remain in the study for up to approximately 13 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
Male participants:
Has a diagnosis of moderate to severe -C (cigarette smoking COPD) or COPD-P (biomass and pollution exposure COPD) according to the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Criteria [1, 2].
Lung impairment will be determined with post-bronchodilator spirometry.
Exclusion Criteria:
Participants must not meet any of the exclusion criteria.
History or active , including any potential neoplasm detected via high-resolution CT scan (nodule > 5 mm) detected as part of the screening process.
People with a history of basal cell or squamous cell carcinoma of the skin are eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 2.4 billion SMS cells by oral inhalation via vibrating mesh nebulizer on Days 1, 3, and 6 (total: 7.2 billion cells). Safety and tolerability are reviewed by an independent DSMC through Day 28 prior to Phase 2a enrollment.
Biological: Stem cells
Participants receive the same treatment regimen as Cohort 1: 2.4 billion SMS cells by oral inhalation via vibrating mesh nebulizer on Days 1, 3, and 6 (total: 7.2 billion cells), following DSMC review of Phase 1b safety data.
Biological: Stem cells
The suspension of Small Mobile Stem (SMS) cells will be placed into a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. Participants with moderate to severe chronic obstructive pulmonary disease (COPD) will breathe in the mist containing the SMS cells through a mouthpiece. The treatment will be given at the study site on Days 1, 3, and 6. Each treatment will contain 2.4 billion SMS cells and will take approximately 30 minutes to complete. This is a Phase 1b/2a study designed to evaluate the safety, tolerability, and potential effects of SMS cells in people with moderate to severe COPD.
Also known as: Small Molecule Stem (SMS) Cells
Adverse events (AEs)
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) graded using CTCAE Version 6.0, and incidence of treatment-related TEAEs, Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
Time frame: Baseline through 12 months
Phase 1b: Dose-limiting toxicities (DLTs)
Incidence of DLTs and and participant stopping-rule events during Phase 1b safety review period prior to Phase 2a expansion
Time frame: Baseline through Day 28
Number of Participants With Clinically Significant Changes From Baseline in Hematology Laboratory Parameters
Number of participants with at least one clinically significant change from baseline in hematology laboratory parameters, as determined by the investigator based on the laboratory reference range, magnitude of change from baseline, and clinical relevance. Hematology assessments include protocol-specified parameters such as hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and platelet count. Participants with one or more clinically significant hematology abnormalities will be counted once for this outcome measure.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Serum Chemistry Laboratory Parameters
Number of participants with at least one clinically significant change from baseline in serum chemistry laboratory parameters, as determined by the investigator based on the laboratory reference range, magnitude of change from baseline, and clinical relevance. Serum chemistry assessments include protocol-specified measures of renal function, hepatic function, electrolytes, glucose, and other chemistry parameters. Participants with one or more clinically significant serum chemistry abnormalities will be counted once for this outcome measure.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant ECG Abnormalities
Number of participants with at least one clinically significant electrocardiogram abnormality, as determined by the investigator. ECG assessment will include heart rate, PR interval, QRS duration, QT interval, and corrected QT interval (QTc). Participants with one or more clinically significant ECG abnormalities will be counted once for this outcome measure.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Systolic Blood Pressure
Number of participants with a clinically significant change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg), as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Diastolic Blood Pressure
Number of participants with a clinically significant change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg), as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Heart Rate
Number of participants with a clinically significant change from baseline in heart rate, measured in beats per minute, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Respiratory Rate
Number of participants with a clinically significant change from baseline in respiratory rate, measured in breaths per minute, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Peripheral Oxygen Saturation
Number of participants with a clinically significant change from baseline in peripheral oxygen saturation (SpO2), measured as percent oxygen saturation by pulse oximetry, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Abnormal Physical Examination Findings
Number of participants with at least one new or worsened clinically significant abnormal finding identified during physical examination after study treatment, as determined by the investigator. Participants with multiple clinically significant physical examination findings will be counted once for this outcome measure.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Pre-Dose FEV1
Number of participants with a clinically significant change from baseline in pre-dose forced expiratory volume in 1 second (FEV1), measured in liters by spirometry, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Pre-Dose to Post-Dose FEV1
Number of participants with a clinically significant change in forced expiratory volume in 1 second (FEV1) from the pre-dose measurement to the protocol-specified post-dose measurement, measured in liters by spirometry, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Baseline in Pre-Dose FVC
Number of participants with a clinically significant change from baseline in pre-dose forced vital capacity (FVC), measured in liters by spirometry, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Clinically Significant Changes From Pre-Dose to Post-Dose FVC
Number of participants with a clinically significant change in forced vital capacity (FVC) from the pre-dose measurement to the protocol-specified post-dose measurement, measured in liters by spirometry, as determined by the investigator based on the magnitude of change and clinical relevance.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Treatment-Emergent Hypersensitivity Reactions
Number of participants experiencing at least one treatment-emergent hypersensitivity reaction during or following administration of study treatment. Hypersensitivity reactions will be identified by the investigator based on protocol-defined clinical signs and symptoms, including allergic or systemic hypersensitivity manifestations. Participants experiencing more than one hypersensitivity reaction will be counted once for this outcome measure.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Number of Participants With Treatment-Emergent Inhalation-Related Reactions
Number of participants experiencing at least one treatment-emergent respiratory or inhalation-related reaction during or following nebulized study treatment. Reactions may include protocol-defined respiratory signs or symptoms such as cough, wheezing, chest tightness, dyspnea, bronchospasm, or clinically significant oxygen desaturation. Participants experiencing more than one inhalation-related reaction will be counted once for this outcome measure.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Spirometry
Within-participant absolute change from baseline in post-bronchodilator Forced Expiratory Volume in One Second (FEV1), measured in liters (L), performed according to ATS/ERS standards
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Spirometry
Within-participant change from baseline in post-bronchodilator FEV1 z-score, calculated using GLI Global reference equations
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Spirometry
Within-participant change from baseline in Percent Predicted FEV1 (ppFEV1), measured in percentage points and calculated using GLI Global reference equations
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Spirometry
Within-participant change from baseline in Forced Vital Capacity (FVC), measured in liters (L), performed according to ATS/ERS standards
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Spirometry
Within-participant change from baseline in FEV1/FVC Ratio, measured as a percentage (%)
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Oscillometry
Within-participant change from baseline in respiratory system Resistance (Rrs) over differing frequencies, measured in cmH2O/L/s, performed according to ERS technical standards
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Oscillometry
Within-participant change from baseline in respiratory system Reactance (Xrs) over differing frequencies, measured in cmH2O/L/s, performed according to ERS technical standards
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Oscillometry
Within-participant change from baseline in Reactance Area (AX), measured in cmH20/L
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Plethysmography
Within-participant change from baseline in Functional Residual Capacity (FRC), measured in liters (L), performed according to ATS/ERS standards
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Plethysmography
Within-participant change from baseline in Total Lung Capacity (TLC), measured in liters (L), performed according to ATS/ERS standards
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Plethysmography
Within-participant change from baseline in Ratio of Residual Volume (RV/TLC), measured as a percentage (%)
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
Within-participant change from baseline in DLCO
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Six-Minute Walk Test (6MWT)
Within-participant change from baseline in 6MWT total distance, heart rate, oxygen saturation, fatigue score, and dyspnea score
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
Fractional Exhaled Nitric Oxide (FeNO)
Within-participant change from baseline in FeNO
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
St. George's Respiratory Questionnaire (SGRQ)
Within-participant change from baseline in St. George's Respiratory Questionnaire total score. Total score ranges from 0 to 100, with higher scores indicating worse respiratory health status and greater impairment in health-related quality of life. Lower scores indicate better outcomes.
Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
COPD exacerbations
Number of exacerbations, time to first exacerbation, exacerbations requiring systemic corticosteroids or antibiotics, emergency department visits, and hospitalizations
Time frame: Baseline through 12 months
Computed Tomography (CT)
CT lung densitometry
Time frame: Baseline and 12 months
Plan to share: No — De-identified data will be published in a peer review scientific journal or presented at a scientific conference. There is no plan at this stage to make IPD available.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 21 phase 1/2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stem Cell
Pulmonary Disease, Chronic Obstructive →
SMSbiotech